论文部分内容阅读
Clinical trials of mesenchymal stem cell (MSC) therapy have shown promise for the treatment of cardiovascular disease including heart failure and critical limb ischemia, However, the efficiency of such therapy is limited by poor cell survival and engraftment,Growth hormone releasing hormone (GHRH) regulates growth and development through pleiotropic actions on multiple target cell and tissue types.